Research at Oslo University Hospital

Understanding how abscission between daughter cells during the final stage of cell division, cytokinesis, is accurately controlled is relevant for cancer, because failure in this process may give rise to binucleate cells and in the next cell division chromosomal missegregation, which might cause aneuploidy, a common feature of cancer cells.  In a recent issue of Current Biology, Lie-Jensen and co-authors elucidate a mechanism by which the abscission machinery is recruited to the midbody in the fruit fly Drosophila melanogaster during abscission.

The major national Norwegian newspaper Aftenposten has recently presented the research of Jan Terje Andersen's "Laboratory of Adaptive Immunity and Homeostasis" group in a feature article entitled "Antistoffer may lead to new HIV medicine.

The goal is a brand new long-acting, preventive HIV medicine that is adapted to the most vulnerable among us.

Recently Oslo University Hospital was awarded by the European Commission the first prize for best innovative science 2019, for the inception of the idea of the ongoing Future and Emerging Technologies Open project: LUMIBLAST, coordinated by Kristian Berg and Theodossis Theodossiou.

The European Society of Medical Oncology (ESMO) Congress 2019 was held in Barcelona September 27th - October 1st, with tens of thousands participants and 3904 abstracts, The Norwegian newspaper for health and medicine - Dagens Medisin - has published several articles presenting Oslo University Hospital researchers contributions. Some of the interviews are shown as videos.

In a study just published in Nature Neuroscience, Tobias Kaufmann and colleagues at NORMENT reported that several psychiatric and neurological disorders are associated with an apparent aging of the brain.

The researchers analysed brain images from more than 45.000 individuals, including data on individuals with different psychiatric and neurological disorders. Several of these disorders were associated with an apparent aging of the brain, with particular strong effects in dementia, multiple sclerosis and schizophrenia.

The European Commission has awarded prizes to Europe's most promising innovations emerging from EU funded research and innovation projects. 
The prize for Innovative Science, which recognizes cutting-edge science underpinning tomorrow's technological advances, was awarded to Oslo University Hospital for their work to bring Lumiblast, a minimally-invasive clinical treatment for cancer cells in hard to reach areas such as brain cancers, closer to clinical use. The OUH Lumiblast team consists of professor Kristian Berg, dr. Theodossis Theodossiou and dr. Quian Peng.

The Center for Heart Failure Research (CHFR) was established in 2002 and has since then promoted the integration of high quality research from bench to bedside. Center members have a broad range of expertise, covering state-of-the-art gene technology, protein function, integrative physiology in pathophysiological models and clinical studies. This collective knowledge and active research collaboration has resulted in more than 200 scientific publications each year.

The Annual Symposiums that began in 2003 have constituted an important platform for networking, introduction of up-and-coming academic talents, along with impressive research results, not to mention the presence of important international speakers shedding light on recent advancements in cardiovascular research.

GE Vingmed Ultrasound together with Oslo University Hospital, the University of Oslo, KU Leuven, the University of Maastrich, Jessa Hospital in Belgium and Medaphor were recently awarded 1.6 million euros for a Marie Curie project that will utilize artificial intelligence to diagnose a number of heart disorders. Several of the international partners in the new project have previously been central to CCI's international research collaboration.

The project SECRET (Exploration of the SECRETory pathway for cancer therapy) has been funded 4 mill EUR from H2020 to establish a Marie Skłodowska-Curie Innovative Training Network (H2020-MSCA-ITN). The objective of SECRET is to improve the understanding of the mutual regulation of the secretory pathway and cell signaling to identify and interrogate novel diagnostic and therapeutic strategies for application in breast- and colorectal cancer. Two Norwegian researchers are partners, Prof Gunhild M. Mælandsmo, Institute for Cancer Research (ICR), Oslo University Hospital and Prof Hesso Farhan, Institute of Basic Medical Science (IMB), University of Oslo, together receiving funding for three Early Stage Researchers (ERS).